Supplementary Table 4. Adverse events that occurred during treatment in 10% or more patients receiving first-line ICI+TKI.

Adverse event	Any grade, n (%)	Grade⩾3, n (%)
Any event	44 (100)	7 (15.9%)
Diarrhea	30 (68.2)	0
Palmar–plantar erythrodysesthesia syndrome	30 (68.2)	0
Hypothyroidism	27 (61.4)	0
Proteinuria	26 (59.1)	1 (2.3%)
Increased triglyceride	26 (59.1)	1 (2.3%)
Increased blood creatinine	24 (54.5)	0
Dysphonia	23 (52.3)	0
Hypertension	17 (38.6)	0
Rash	17 (38.6)	2 (4.5%)
Increased corticotropin	16 (36.4)	0
Fatigue	13 (29.5)	0
Hypercholesterolemia	11 (25.0)	0
Decreased weight	11 (25.0)	0
Decreased lymphocyte count	11 (25.0)	1 (2.3%)
Nausea	10 (22.7)	0
Decreased appetite	10 (22.7)	0
Vomiting	10 (22.7)	0
Hyperuricemia	8 (18.2)	0
Dizziness	8 (18.2)	0
Throat pain	8 (18.2)	0
Hematuria	6 (13.6)	0
Increased alkaline phosphatase	6 (13.6)	0
Constipation	6 (13.6)	0
Anemia	6 (13.6)	0
Headache	5 (11.4)	0
Hypocalcemia	5 (11.4)	0
Increased alanine transaminase	5 (11.4)	1 (2.3%)